Maintenance treatment with trofosfamide in patients with advanced soft tissue sarcoma – a retrospective single-centre analysis
DOI:
https://doi.org/10.2340/1651-226X.2025.42356Keywords:
Soft Tissue Sarcoma, Trofosfamide, Maintenance, Systemic Therapy, MetastasisAbstract
Background: The prognosis of patients with advanced soft tissue sarcoma (STS) remains dismal. Trofosfamide (TRO) has been proposed as a well-tolerated oral maintenance therapy. This retrospective analysis aims to determine the value of this therapy.
Methods: Fifty-nine patients with advanced STS who received TRO maintenance therapy between 2016 and 2022 were reviewed and analysed regarding clinical parameters and outcomes.
Results: The median age was 48 years; the most common histological subtype was synovial sarcoma (n = 22, 37%), and 71% of patients (n = 42) presented with metastatic disease. No radiological evidence of disease (NED) before the start of maintenance was reported in 36% of patients (n = 21). The median follow-up was 38.2 months with a median maintenance duration of 9.0 months. The median event-free survival (EFS) and overall survival (OS) were 9.5 and 33.2 months, respectively. In metastatic patients achieving NED before the initiation of TRO, the median EFS was 29.4 months, while the median OS was not reached. In metastatic patients with anthracycline + ifosfamide (AI) as first-line induction therapy without prior metastasis-directed local therapy, the median EFS and OS from the start of AI were 13.9 and 26.8 months, respectively. Multivariate analysis of the overall cohort demonstrated that NED before the start of maintenance was significantly associated with a prolonged EFS (p = 0.024, hazard ratio [HR] = 0.26), and G2 histology correlated with longer OS (p = 0.030, HR = 0.16, reference: G3).
Interpretation: Oral maintenance therapy with TRO appears to improve outcomes in patients with advanced STS. Metastatic patients who achieve NED through prior metastasectomy may particularly benefit from TRO maintenance.
Downloads
References
Beckingsale TB, Shaw C. Epidemiology of bone and soft-tissue sarcomas. Orthop Trauma. 2017;31:144–50.
https://doi.org/10.1016/j.mporth.2017.03.005 DOI: https://doi.org/10.1016/j.mporth.2017.03.005
Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchre D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers sarcoma group. Cancer. 2001;91:1914–26.
https://doi.org/10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3 DOI: https://doi.org/10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3
Italiano A, Mathoulin-Pelissier S, Le Cesne A, Terrier P, Bonvalot S, Collin F, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049–54.
https://doi.org/10.1002/cncr.25538 DOI: https://doi.org/10.1002/cncr.25538
Lochner J, Menge F, Vassos N, Hohenberger P, Kasper B. Prognosis of patients with metastatic soft tissue sarcoma: advances in recent years. Oncol Res Treat. 2020;43:613–19.
https://doi.org/10.1159/000509519 DOI: https://doi.org/10.1159/000509519
Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17:150–7.
https://doi.org/10.1200/JCO.1999.17.1.150 DOI: https://doi.org/10.1200/JCO.1999.17.1.150
Pasquali S, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer. 2022;128:85–93.
https://doi.org/10.1002/cncr.33895 DOI: https://doi.org/10.1002/cncr.33895
Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol. 2018;4:483–92.
https://doi.org/10.1001/jamaoncol.2017.4996 DOI: https://doi.org/10.1001/jamaoncol.2017.4996
von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, et al. Soft tissue sarcoma, version 2.2022. J Natl Compr Canc Netw. 2022;20:815–33.
https://doi.org/10.6004/jnccn.2022.0035 DOI: https://doi.org/10.6004/jnccn.2022.0035
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.
https://doi.org/10.1016/S1470-2045(14)70063-4 DOI: https://doi.org/10.1016/S1470-2045(14)70063-4
Falk AT, Moureau-Zabotto L, Ouali M, Penel N, Italiano A, Bay J-O, et al. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. Clin Oncol (R Coll Radiol). 2015;27:48–55.
https://doi.org/10.1016/j.clon.2014.09.010 DOI: https://doi.org/10.1016/j.clon.2014.09.010
Savina M, Le Cesne A, Blay J-Y, Ray-Coquard I, Mir O, Toulmonde M, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15(1):78.
https://doi.org/10.1186/s12916-017-0831-7 DOI: https://doi.org/10.1186/s12916-017-0831-7
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022;23:1044–54.
https://doi.org/10.1016/S1470-2045(22)00380-1 DOI: https://doi.org/10.1016/S1470-2045(22)00380-1
Dirksen U. International Euro ewing trial for treatment optimisation in patients with ewing sarcoma [homepage on the Internet]. [cited 2024 July 15] Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004153-93/DE#A
Boos J, Küpker F, Blaschke G, Jürgens H. Trofosfamide metabolism in different species – ifosfamide is the predominant metabolite. Cancer Chemother Pharmacol. 1993;33:71–6.
https://doi.org/10.1007/BF00686026 DOI: https://doi.org/10.1007/BF00686026
Gebrauchsinformation: Ixoten 50 mg Filmtabletten, Baxter Oncology GmbH, Deerfield, United States of America, 2021
Blomqvist C, Wiklund T, Pajunen M, Virolainen M, Elomaa I. Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol. 1995;36:263–5.
https://doi.org/10.1007/BF00685858 DOI: https://doi.org/10.1007/BF00685858
Kollmannsberger C, Brugger W, Hartmann JT, Maurer F, Böhm P, Kanz L, et al. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs. 1999;10(5):456–6.
https://doi.org/10.1097/00001813-199906000-00004 DOI: https://doi.org/10.1097/00001813-199906000-00004
Hartmann J, Oechsle K, Mayer F, Kanz L, Bokemeyer C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res. 2003;23(2C):1899–901.
Reichardt P, Pink D, Tilgner J, Kretzschmar A, Thuss-Patience PC, Dörken B. Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis. Onkologie. 2002;25:541–6.
https://doi.org/10.1159/000068625 DOI: https://doi.org/10.1159/000068625
Hartmann JT, Kopp HG, Gruenwald V, Piperno-Neumann S, Kunitz A, Hofheinz R, et al. Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. Eur J Cancer. 2020;124:152–60.
https://doi.org/10.1016/j.ejca.2019.10.016 DOI: https://doi.org/10.1016/j.ejca.2019.10.016
Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33:37–42.
https://doi.org/10.1002/ijc.2910330108 DOI: https://doi.org/10.1002/ijc.2910330108
Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113:70–84.
https://doi.org/10.32074/1591-951X-213 DOI: https://doi.org/10.32074/1591-951X-213
Hartmann JT, Issels RD, Reichardt P, Schütte J, Schmoll HJ, Kegel T. Randomisierte Phase II-Studie von Trofosfamid versus Adriamycin bei älteren Patienten mit unvorbehandeltem metastasiertem Weichteilsarkom. 2004. AIO (Allgemeine Internistische Onkologie) study protocol. [Accessed July 15, 2024] Available from https://www.uk-essen.de/fileadmin/tumorforschung/AG_Bauer/Studien/AIO_Protokoll_002.pdf.
Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Published online 2017. Accessed July 15, 2024.
Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753-1759.
https://doi.org/10.1200/JCO.2006.07.3049 DOI: https://doi.org/10.1200/JCO.2006.07.3049
Burkhard-Meier A, Grube M, Jurinovic V, Agaimy A, Albertsmeier M, Berclaz LM, et al. Unraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma – a retrospective multicenter study of the Bavarian university hospitals. Eur J Surg Oncol. 2024;50(12):108619.
https://doi.org/10.1016/J.EJSO.2024.108619 DOI: https://doi.org/10.1016/j.ejso.2024.108619
Stamenovic D, Hohenberger P, Roessner E. Pulmonary metastasectomy in soft tissue sarcomas: a systematic review. J Thorac Dis. 2021;13:2649–60.
https://doi.org/10.21037/jtd-2019-pm-13 DOI: https://doi.org/10.21037/jtd-2019-pm-13
S3-Leitlinie Adulte Weichgewebesarkome. 2021; Version 1. [Accessed July 15, 2024] Available from https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Adulte_Weichgewebesarkome/LL_Weichgewebesarkome_Langversion_1.1.pdf.
Medicines Agency E. Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man. Published online 2012. [Accessed June 20, 2024] Available from www.ema.europa.eu.
Demetri GD, Von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34:786–93.
https://doi.org/10.1200/JCO.2015.62.4734 DOI: https://doi.org/10.1200/JCO.2015.62.4734
Van Der Graaf WTA, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.
https://doi.org/10.1016/S0140-6736(12)60651-5 DOI: https://doi.org/10.1016/S0140-6736(12)60651-5
Le Cesne A, Bauer S, Demetri GD, Han G, Dezzani L, Ahmad Q, et al. Safety and efficacy of pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer. 2019;19:794.
https://doi.org/10.1186/S12885-019-5988-3 DOI: https://doi.org/10.1186/s12885-019-5988-3
Palumbo R, Palmeri S, Antimi M, Gatti C, Raffo P, Villani G, et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol. 1997;8:1159–62.
https://doi.org/10.1023/A:1008279426654 DOI: https://doi.org/10.1023/A:1008279426654
Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas. J Clin Oncol. 2007;25:2755–63.
https://doi.org/10.1200/JCO.2006.10.4117 DOI: https://doi.org/10.1200/JCO.2006.10.4117
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Anton Burkhard-Meier, Vera Valerie Rechenauer, Luc M. Berclaz, Vindi Jurinovic, Markus Albertsmeier, Hans Roland Dürr, Sinan E. Güler, Michael Hoberger, Alexander Klein, Thomas Knösel, Wolfgang G. Kunz, Nina-Sophie Schmidt-Hegemann, Michael von Bergwelt-Baildon, Lars H. Lindner, Dorit Di Gioia
This work is licensed under a Creative Commons Attribution 4.0 International License.
